Chicago Capital LLC Grows Stock Holdings in Stryker Co. (NYSE:SYK)

Chicago Capital LLC lifted its holdings in Stryker Co. (NYSE:SYK - Free Report) by 3.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 195,052 shares of the medical technology company's stock after purchasing an additional 5,841 shares during the period. Stryker comprises 1.9% of Chicago Capital LLC's holdings, making the stock its 19th biggest position. Chicago Capital LLC owned 0.05% of Stryker worth $70,228,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Dunhill Financial LLC lifted its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after buying an additional 37 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Stryker in the 3rd quarter worth $36,000. Crews Bank & Trust purchased a new stake in shares of Stryker during the 4th quarter worth $39,000. HBW Advisory Services LLC bought a new stake in Stryker during the third quarter valued at about $42,000. Finally, Hara Capital LLC purchased a new position in Stryker in the third quarter valued at about $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

SYK traded down $2.85 on Thursday, reaching $396.24. The stock had a trading volume of 1,124,025 shares, compared to its average volume of 1,511,213. The business's 50-day moving average price is $377.08 and its two-hundred day moving average price is $364.24. The company has a market cap of $151.05 billion, a P/E ratio of 51.06, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. Sell-side analysts forecast that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.85%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent analyst reports. Wells Fargo & Company raised their price target on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Morgan Stanley upgraded shares of Stryker from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, January 30th. Evercore ISI raised their price objective on Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Finally, Robert W. Baird upped their target price on Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $419.37.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.